We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

1 hedge funds and large institutions have $172K invested in VanEck Vectors Generic Drugs ETF in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% less capital invested

Capital invested by funds: $201K → $172K (-$29.2K)

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$24K
2
APA
American Portfolios Advisors
New York
-$8.92K
Name Holding Trade Value Shares
Change 		Change in
Stake
APA
1
American Portfolios Advisors
New York
$172K -$8.92K -362 -5%
Bank of America
2
Bank of America
North Carolina
– -$24K -1,000 Closed

GNRX Hedge Fund Activity: Q2 2018 in Review

1 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q2 2018, worth a combined $172K — down 15% from $201K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of GNRX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was Bank of America, exiting entirely with an estimated $24K sold.

  • 1 institutional investor held VanEck Vectors Generic Drugs ETF (GNRX) as of Q2 2018, down from 2 in Q1 2018.
  • Funds reported $172K of VanEck Vectors Generic Drugs ETF stock for Q2 2018, down 15% quarter-over-quarter.
  • 0 funds opened new VanEck Vectors Generic Drugs ETF positions in Q2 2018 and 1 closed out, a net change of -1 holder.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q2 2018 was Bank of America, an estimated $24K sold.

Based on aggregated 13F filings for Q2 2018.